Docetaxel.

Docetaxel (Taxotere) was reviewed for its preclinical and clinical profiles, showing significant activity in various cancers, including breast, lung, ovarian, and head and neck cancers. In phase I studies, the major dose-limiting toxicity was neutropenia, with other side effects like mucositis, hypersensitivity reactions, neurotoxicities, cutaneous reactions, alopecia, and asthenia. Phase II trials confirmed its efficacy, with neutropenia as the principal side effect. Hypersensitivity reactions were common but manageable with premedication. Ongoing studies aimed to optimize its use in combination regimens and to mitigate side effects.